Lupin launches generic equivalent of Sunovion Pharmas Brovana in US markets

The global pharma major, Lupin Limited announced today that it has launched the authorised generic version of Brovana inhalation solution (Arformoterol Tartrate) of Sunovion Pharmaceuticals in the strengths of 15 mcg/2ml unit dose vials.   

Arformoterol Tartrate is indicated for the long-term maintenance treatment of Bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis & emphysema.   

Sunovion's maintenance COPD drug, Brovana has been weathering competition in a crowded field, which will be amped-up by generics, this year with the drug patent expiring. Several generics makers have scored tentative approvals from United States Food & Drug Administration (USFDA). They include Teva, Cipla, and Lupin, as per the federal agency.   

The stock of Lupin Ltd closed at Rs 1,231.35, down by 0.08 per cent against its previous close of Rs 1,232.35 on BSE.